Ultragenyx picks up $65M investment, asset in Takeda rare disease R&D pact

Handshake

Ultragenyx Pharmaceutical ($RARE) has signed off on a rare genetic disease pact with Takeda. The deal establishes Ultragenyx as a de facto rare disease R&D outpost of Takeda, which is funneling preclinical programs and funding into its partner in return for an opportunity to pick up Asian rights to any assets that reach the market.

In the near term, the focus of the deal is on the transfer of assets from Takeda to Ultragenyx. Takeda has granted the rare disease specialist an exclusive license to one of its preclinical assets in a certain, undisclosed therapeutic field. And Ultragenyx has an exclusive option to co-develop the drug in other therapeutic areas. The asset could be the first of 6 to transfer from Takeda to Ultragenyx, which has secured itself first dibs on up to 5 more rare disease prospects in Takeda’s pipeline.

Ultragenyx will decide which, if any, of the programs it wants after a joint research committee it has set up with Takeda runs initial validation activities. If everything goes to plan, Ultragenyx will gain access to a source of pipeline prospects that can support its ambitions to bring a steady stream of rare disease drugs to market.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

“This broad collaboration provides Ultragenyx with a product opportunity that is approaching clinical-stage development as well as a potential continued source of new product candidates that will help us achieve our goal of bringing a new therapy into the clinic every one to two years,” Dr. Emil Kakkis, CEO of Ultragenyx, said in a statement.

To bankroll the work, Takeda is buying $25 million of Ultragenyx stock and paying a $15 million premium to sweeten the deal. Ultragenyx has the option to request a further $25 million investment from Takeda within the next 12 months. Takeda is presenting the investment as a way to fund the advance of a set of pipeline prospects that could come to bolster its own business.

In return for the preclinical assets and funding, Takeda has picked up an option on the Asian rights to any licensed products that emerge from the collaboration. And the company can claim the Japanese rights to one of of Ultragenyx’s pipeline programs.

- read the statement

Related Articles:
Ultragenyx launches an RNA collaboration with upstart Arcturus
Startup Ultragenyx snags PhII program for growing rare-disease pipeline

Read more on

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.